Self-assembled residence devices and related methods

Patent metadata

Field	Value
Publication number	US-10849853-B2
Application number	US-201515317628-A
Country	US
Kind code	B2
Filing date	Jun 11, 2015
Priority date	Jun 11, 2014
Publication date	Dec 1, 2020
Grant date	Dec 1, 2020

Abstract

Residence devices as well as their related methods of manufacture and use are generally provided. In some embodiments, a residence device includes a plurality of self-assembling structures that assemble in vivo to form an aggregate structure. Each structure of the plurality of structures includes a first side and a first attachment point that attaches to a second attachment point on another structure of the plurality of structures. The aggregate structure may be sized and shaped to maintain an in vivo position relative to an internal orifice of a subject. The attachment between the first and second attachment points may degrade after a period of time.

First claim

What is claimed is:

1. A residence device comprising:
a plurality of separate self-assembling structures, each structure of the plurality of structures comprising:
a first side; and
a first attachment point on the first side, wherein the first attachment point is configured to attach in vivo to a second attachment point on another structure of the plurality of structures,
wherein the plurality of structures are sized and shaped to form an aggregate structure that is sized and shaped to maintain an in vivo position relative to an internal orifice,
wherein at least some of the plurality of self-assembling structures comprise a through hole, wherein each through hole extends from a first side of an associated self-assembling structure to a second opposing side of the associated self-assembling structure and is sized and shaped to permit passage of ingestible materials through the aggregate structure,
wherein the internal orifice is a gastric pyloric orifice, and
wherein an attachment between the first attachment point and the second attachment point is configured to degrade after a period of time when the plurality of structures are placed in vivo such that at least a portion of the residence device is capable of passing through the internal orifice.

2. The residence device of claim 1 , wherein degradation of the attachment is caused by at least one of biodegradation of the attachment and/or swelling of at least one structure of the plurality of structures.

3. The residence device of claim 1 , wherein at least one structure of the plurality of structures comprises at least one active substance.

4. The residence device of claim 3 , wherein the at least one active substance includes a therapeutic agent, a diagnostic agent, and/or an enhancement agent.

5. The residence device of claim 1 , wherein each structure of the plurality of structures comprises at least one of polycaprolactone, poly(ethylene-co-vinyl acetate), polyethylene glycol, a food grade cross-linked polymer, and/or an enteric elastomer.

6. The residence device of claim 1 , wherein the first and second attachment points include at least one of magnets, protein-ligand complexes, and/or host-guest complexes.

7. The residence device of claim 6 , wherein a protein-ligand complex comprises biotin and streptavidin.

8. The residence device of claim 6 , wherein a host-guest complex comprises cyclodextrin and adamantane.

9. The residence device of claim 1 , wherein each structure of the plurality of structures further comprises an exterior surface having a polygonal shape.

10. The residence device of claim 9 , wherein the polygonal shape is at least one of a triangle, a square, a rectangle, and/or a pentagon.

11. The residence device of claim 1 , wherein each structure of the plurality of structures further comprises an interior surface and an exterior surf ace opposite the interior surface, and,
wherein the first side extends between the interior surface and the exterior surface, and wherein the first side is oriented at an angle between about 58.3° and about 66° with respect to the exterior surface.

12. The residence device of claim 11 , wherein the first side is oriented at an angle between about 62° and about 63.5° with respect to the exterior surface.

13. The residence device of claim 1 , wherein each structure of the plurality of structures has a circumscribing radius of about 0.6 cm to about 1.7 cm.

14. The residence device of claim 1 , wherein each structure of the plurality of structures occupies a volume of about 300 mm 3 to about 1300 mm 3 .

15. The residence device of claim 1 , wherein each structure of the plurality of structures is configured to be at least one of ingested and/or administered orally.

16. The residence device of claim 1 , wherein the aggregate structure includes a void space within an interior of the aggregate structure.

17. The residence device of claim 16 , wherein the through holes are configured to provide fluid communication between the void space and an exterior of the aggregate structure.

18. The residence device of claim 3 , wherein the at least one active substance includes a plurality of active substances.

19. The residence device of claim 3 , wherein the at least one active substance is a biological macromolecule, a small molecule, a vitamin, and/or a supplement.

20. The residence device of claim 3 , wherein the at least one active substance is at least one selected from the group of prednisone, risperidone, memantine, methadone, rosuvastatin, doxycycline, buprenorphine, aripiprazole, meloxicam, and/or azithromycin.

21. The residence device of claim 3 , wherein the at least one active substance is at least one selected from the group of analgesics, anti-analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antipsychotic agents, neuroprotective agents, anti-proliferatives, anti-cancer agents, antihistamines, antimigraine drugs, hormones, prostaglandins, antimicrobials, antibiotics, antifungals, antivirals, antiparasitics, antimuscarinics, anxioltyics, bacteriostatics, immunosuppres sant agents, sedatives, hypnotics, antipsychotics, bronchodilators, anti-asthma drugs, cardiovascular drugs, anesthetics, anticoagulants, inhibitors of an enzyme, steroidal agents, nonsteroidal antiinflammatory agents, steroidal anti-inflammatory agents, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, parasympathomimetics, stimulants, anorectics, anti-narcoleptics, proteins, peptides, nucleic acids, gene constructs, rosuvastatin, selective serotonin reuptake inhibitors, blood thinning agents, steroids, F, antagonists, cardiac glycosides, alpha blockers, cholesterol absorption inhibitors, metabolites, opioids, proton-pump inhibitors, anti-malarial agents, quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, a sulfonamide, mefloquine, atovaquone, primaquine, halofantrine, doxycycline, clindamycin, artemisinin, artemisinin derivatives, prednisone, risperidone, memantine, methadone, buprenorphine, aripiprazole, meloxicam, azithromycin, substance abuse treatments, hormonal contraceptives, nutritional supplements, vitamin supplements, and mineral supplements.

Assignees

• Massachusetts Inst Technology
• Brigham & Womens Hospital Inc

Inventors

• Bellinger Andrew
• Zhang Shiyi
• Traverso Carlo Giovanni
• Langer Robert S
• Mo Stacy
• Lin Jiaqi
• Diciccio Angela
• Glettig Dean Liang
• Wood Jr Lowell L
• Eckhoff Philip A

Classifications

• C08G63/08

  Lactones or lactides · CPC title

• C08G18/73

  acyclic · CPC title

• C08G18/4277

  Caprolactone and/or substituted caprolactone · CPC title

• A61K47/6901

  Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title

• A61K47/58

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin · CPC title